PROF Earnings & Financial Statements
Profound Medical Corp.
$6.91
+$1.23(+21.65%)
53
Overall
55
Value
50
Tech
55
Quality
Market Cap
$209.74M
Volume
2.96M
52W Range
$4.80 - $8.95
Target Price
$11.13
PROF earnings and financial statements: Profound Medical Corp.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PROF Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $16.10M | $10.68M | $7.20M | $6.68M | $6.87M |
| Cost of revenue | $4.71M | $3.64M | $2.89M | $3.66M | $3.92M |
| Operating income | -$41.25M | -$33.06M | -$28.65M | -$29.60M | -$30.29M |
| EBITDA | -$41.76M | -$34.50M | -$26.37M | -$62.04M | -$28.65M |
| Net income | -$42.57M | -$35.72M | -$27.17M | -$63.82M | -$30.70M |
| EPS (diluted) | $1.41 | $1.12 | $-1.34 | $1.38 | $-1.50 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $77.47M | $70.23M | $43.96M | $64.42M | $86.78M |
| Total liabilities | $10.83M | $9.81M | $7.73M | $5.77M | $6.16M |
| Shareholders’ equity | $66.43M | $60.42M | $31.22M | $52.00M | $80.62M |
| Cash and equivalents | $59.72M | $54.91M | $26.21M | $46.52M | $67.15M |
| Long-term debt | $4.50M | $3.13M | $504.0K | $817.0K | $1.13M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$38.21M | -$23.39M | -$22.61M | -$25.80M | -$22.36M |
| Free cash flow | -$38.45M | -$23.39M | -$22.61M | -$25.80M | -$22.36M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PROF | $6.91 | +21.7% | 2.96M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |